^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PCSK9 inhibitor

    Related drugs:
    6d
    STREAMLINE: Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    ACS: Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes (clinicaltrials.gov)
    P3, N=300, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    APOB (Apolipoprotein B)
    7d
    A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting (clinicaltrials.gov)
    P=N/A, N=1871, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion • Real-world evidence
    12d
    PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS) (clinicaltrials.gov)
    P=N/A, N=212, Not yet recruiting, West China Hospital | Trial completion date: Dec 2026 --> Jun 2028 | Initiation date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jun 2026 --> Dec 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    APOB (Apolipoprotein B)
    13d
    Blocking PCSK9 suppresses hepatocellular carcinoma immune escape by decreasing FLI1-mediated SPP1 and PD-L1 expression. (PubMed, J Immunother Cancer)
    PCSK9 promoted HCC immune escape by upregulating SPP1 and PD-L1 via NOTCH3/FLI1 signaling. CRISPR ABE-mediated PCSK9 deficiency and PCSK9 inhibitor parecoxib may serve as effective strategies to inhibit HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) • NOTCH3 (Notch Receptor 3) • SPP1 (Secreted Phosphoprotein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
    |
    PD-L1 expression
    |
    Dynastat (parecoxib)
    13d
    A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia (clinicaltrials.gov)
    P3, N=720, Completed, Shenzhen Salubris Pharmaceuticals Co., Ltd.
    New P3 trial
    16d
    Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity (clinicaltrials.gov)
    P1/2, N=104, Recruiting, Ikaria Bioscience Pty Ltd
    New P1/2 trial
    16d
    A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) (clinicaltrials.gov)
    P3, N=975, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    APOB (Apolipoprotein B)
    16d
    EVACS: Evolocumab in Acute Coronary Syndrome (clinicaltrials.gov)
    P2, N=60, Completed, Johns Hopkins University | Trial completion date: Oct 2024 --> Mar 2025
    Trial completion date
    |
    Repatha (evolocumab)
    19d
    ORIS: Ongericimab Injection Reducing Recurrence of Ischemic Stroke (clinicaltrials.gov)
    P3, N=4398, Not yet recruiting, Beijing Tiantan Hospital
    New P3 trial
    |
    Junshida (ongericimab)
    24d
    PCSK9 Inhibition Protects Against Myocardial Ischemia-Reperfusion Injury in Type 2 Diabetes Rats Via Suppressing Inflammation and Apoptosis. (PubMed, Anatol J Cardiol)
    Alirocumab and atorvastatin effectively attenuated myocardial I/R injury in T2DM by modulating lipid metabolism, inflammation, and apoptosis. Diabetes substantially intensified I/R-induced cardiac injury, underscoring the importance of metabolic control in cardioprotection. #Means they contributed equally to the article.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) • CASP3 (Caspase 3) • NLRC5 (NLR Family CARD Domain Containing 5) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    atorvastatin • Praluent (alirocumab)
    30d
    Alirocumab therapy effectively suppresses colorectal cancer cell Growth and invasion in nude mouse liver-PCSK9 is a key driver of PI3K/Akt/p-Bad-mediated cell proliferation and antiapoptotic signaling. (PubMed, Int J Surg)
    Alirocumab-facilitated 5-FU therapy effectively suppresses PCSK9-promoted CRC proliferation/growth/invasion, highlighting that alirocumab therapy may be an alternative choice of adjuvant therapy in combination with surgery or chemotherapy.
    Preclinical • Journal
    |
    PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) • DLD (Dihydrolipoamide Dehydrogenase)
    |
    5-fluorouracil • Praluent (alirocumab)